JP2024538719A5 - - Google Patents
Info
- Publication number
- JP2024538719A5 JP2024538719A5 JP2024521023A JP2024521023A JP2024538719A5 JP 2024538719 A5 JP2024538719 A5 JP 2024538719A5 JP 2024521023 A JP2024521023 A JP 2024521023A JP 2024521023 A JP2024521023 A JP 2024521023A JP 2024538719 A5 JP2024538719 A5 JP 2024538719A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- taxane
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252995P | 2021-10-06 | 2021-10-06 | |
| US63/252,995 | 2021-10-06 | ||
| PCT/US2022/045895 WO2023059795A1 (en) | 2021-10-06 | 2022-10-06 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538719A JP2024538719A (ja) | 2024-10-23 |
| JP2024538719A5 true JP2024538719A5 (https=) | 2025-10-20 |
Family
ID=84053165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521023A Pending JP2024538719A (ja) | 2021-10-06 | 2022-10-06 | がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240398795A1 (https=) |
| EP (1) | EP4412607A1 (https=) |
| JP (1) | JP2024538719A (https=) |
| KR (1) | KR20240095421A (https=) |
| CN (1) | CN118251218A (https=) |
| AU (1) | AU2022360837A1 (https=) |
| CA (1) | CA3233157A1 (https=) |
| IL (1) | IL311663A (https=) |
| MX (1) | MX2024004171A (https=) |
| WO (1) | WO2023059795A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0922332D0 (en) * | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| WO2016022605A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3191592A1 (en) * | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| IL290341B2 (en) | 2019-09-12 | 2024-11-01 | Mirati Therapeutics Inc | Mta-cooperative prmt5 inhibitors |
| IL293351A (en) * | 2019-12-18 | 2022-07-01 | Pfizer | Once daily cancer treatment regimen with a prmt5 inhibitor |
| WO2021138578A1 (en) * | 2019-12-31 | 2021-07-08 | The Trustees Of Indiana University | Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5 |
-
2022
- 2022-10-06 MX MX2024004171A patent/MX2024004171A/es unknown
- 2022-10-06 US US18/697,932 patent/US20240398795A1/en active Pending
- 2022-10-06 AU AU2022360837A patent/AU2022360837A1/en active Pending
- 2022-10-06 EP EP22800027.9A patent/EP4412607A1/en active Pending
- 2022-10-06 IL IL311663A patent/IL311663A/en unknown
- 2022-10-06 WO PCT/US2022/045895 patent/WO2023059795A1/en not_active Ceased
- 2022-10-06 KR KR1020247014554A patent/KR20240095421A/ko active Pending
- 2022-10-06 CN CN202280067397.9A patent/CN118251218A/zh active Pending
- 2022-10-06 CA CA3233157A patent/CA3233157A1/en active Pending
- 2022-10-06 JP JP2024521023A patent/JP2024538719A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544280A5 (https=) | ||
| JP2025511399A5 (https=) | ||
| JP2025020147A5 (https=) | ||
| JP2023501627A (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| JP6865684B2 (ja) | 非小細胞肺癌に対するキノリン誘導体 | |
| EP2493466B1 (en) | Novel antitumoral use of cabazitaxel | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| CN113573736B (zh) | 经修饰的微rna和它们在治疗癌症中的用途 | |
| JP2024538719A5 (https=) | ||
| JP2003533485A5 (https=) | ||
| WO2017177962A1 (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2021513965A5 (https=) | ||
| JP2024508692A5 (https=) | ||
| JP2021523169A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
| JP2023533937A5 (https=) | ||
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| US10080807B2 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | |
| Parizadeh et al. | Epigenetic drug therapy in the treatment of colorectal cancer | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| US9402847B2 (en) | Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide | |
| CN111939165B (zh) | 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用 | |
| CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
| JP2024520307A5 (https=) | ||
| Ozdemir et al. | Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients |